Funding for this research was provided by:
Instituto de Salud Carlos III (COV20/00286)
Received: 23 June 2020
Accepted: 25 June 2020
First Online: 2 July 2020
Ethics approval and consent to participate
: On April 2<sup>nd</sup>, 2020, a short trial proposal was approved by the <i>Comité de Ética en Investigación</i> of the Hospital Clínic of Barcelona to allow the start of the clinical trial procedures in the COVID-19 emergency situation (trial code HCB/2020/0382, meeting reference 9/2020_Extraordinària). The full trial protocol was approved as an amendment by the same committee on the ordinary meeting of May 14<sup>th</sup>, 2020.The clinical trial was authorized by the Spanish Agency of Drugs and Medical Products (AEMPS) on April 8<sup>th</sup>, 2020 (authorization tracking code FEPZKWTD4D), and the agency approved the full protocol on May 22<sup>nd</sup>, 2020 (authorization tracking code FBVJZBZ766).Informed consent will be obtained from all participants.
: Not applicable.
: The authors declare that they have no competing interests.